OMERS ADMINISTRATION Corp Acquires 48,000 Shares of Cellebrite DI Ltd. $CLBT

OMERS ADMINISTRATION Corp grew its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 85.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 104,166 shares of the company’s stock after acquiring an additional 48,000 shares during the period. OMERS ADMINISTRATION Corp’s holdings in Cellebrite DI were worth $1,435,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Renaissance Technologies LLC increased its position in Cellebrite DI by 14.7% during the 1st quarter. Renaissance Technologies LLC now owns 2,860,639 shares of the company’s stock valued at $39,420,000 after buying an additional 365,700 shares in the last quarter. Siren L.L.C. grew its stake in shares of Cellebrite DI by 107.7% in the first quarter. Siren L.L.C. now owns 311,544 shares of the company’s stock worth $4,293,000 after acquiring an additional 161,544 shares during the last quarter. State of Wyoming purchased a new stake in shares of Cellebrite DI in the first quarter worth $378,000. First Trust Advisors LP increased its holdings in shares of Cellebrite DI by 49.1% during the first quarter. First Trust Advisors LP now owns 136,409 shares of the company’s stock valued at $1,880,000 after acquiring an additional 44,912 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Cellebrite DI by 59.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 7,456 shares of the company’s stock worth $103,000 after purchasing an additional 2,785 shares during the last quarter. Hedge funds and other institutional investors own 45.88% of the company’s stock.

Insiders Place Their Bets

In other news, CRO Marcus Jewell sold 12,658 shares of the firm’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $12.77, for a total transaction of $161,642.66. Following the sale, the executive owned 440,101 shares of the company’s stock, valued at $5,620,089.77. This trade represents a 2.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Thomas E. Hogan sold 103,188 shares of Cellebrite DI stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $15.76, for a total transaction of $1,626,242.88. Following the completion of the sale, the chief executive officer owned 590,777 shares of the company’s stock, valued at $9,310,645.52. This represents a 14.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 158,191 shares of company stock valued at $2,479,438. 5.70% of the stock is owned by insiders.

Cellebrite DI Price Performance

Shares of NASDAQ:CLBT opened at $15.07 on Thursday. Cellebrite DI Ltd. has a 1 year low of $11.02 and a 1 year high of $19.98. The company has a market cap of $3.76 billion, a P/E ratio of 53.82, a PEG ratio of 1.84 and a beta of 1.17. The stock’s fifty day moving average price is $14.27 and its 200-day moving average price is $14.20.

Analyst Ratings Changes

A number of equities analysts recently issued reports on CLBT shares. DA Davidson initiated coverage on shares of Cellebrite DI in a research note on Wednesday, May 27th. They issued a “buy” rating and a $20.00 price target on the stock. Weiss Ratings raised shares of Cellebrite DI from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, May 18th. Finally, Needham & Company LLC dropped their target price on shares of Cellebrite DI from $18.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cellebrite DI currently has an average rating of “Moderate Buy” and an average price target of $21.40.

Cellebrite DI Company Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.